Johnson & Johnson launches Generation Fine, a new movement encouraging patients to expect more from depression treatment and aim for remission

Johnson & Johnson has announced the launch of Generation Fine, a global campaign designed to challenge what it means to feel “fine” in depression care and encourage patients to take the first step toward moving beyond “good enough” by speaking with their healthcare provider. Informed by a global survey of patients and healthcare providers across seven countries and four continents, the campaign highlights a concerning reality: nearly four in five patients living with major depressive disorder (MDD) do not believe antidepressants will help them reach remission. Developed in collaboration with leading mental health advocates and drawing on the expertise of Mental Health America, Generation Fine shines a light on the distinct challenges faced by people living with depression and provides resources to support more meaningful conversations about their care, including the possibility of remission.

“Depression doesn’t look the same for everyone, but it is often treated with the same one-size-fits-all approach,” said Jessica Jackson, vice president of alliance development at Mental Health America. “This disconnect can leave people feeling unseen or misunderstood, while stigma and societal pressures make it even harder to seek help. We need to change the conversation and create opportunities where all people feel empowered to say, ‘I’m not okay.’”

MDD, or clinical depression, is one of the most prevalent psychiatric disorders, affecting an estimated 332 million people worldwide. In the US alone, more than 22 million adults live with the condition. While oral antidepressants are effective for some, studies suggest that around two in three people living with MDD continue to experience residual or ongoing depressive symptoms while on treatment, meaning many patients are left settling for outcomes that are just “fine.”

The Generation Fine global survey findings highlight the everyday burden of ongoing symptoms that people with MDD continue to face while on treatment:

Feeling “fine” on treatment is accepted as good enough: nearly four in five patients believe antidepressants are unlikely to address all of their symptoms or help them reach remission.

Ongoing depression symptoms are a significant burden: almost three in four patients said their residual symptoms have a real impact on their daily lives. Nearly 90% reported their symptoms affect how they perform at work, and more than half said they isolate themselves from others more frequently than they normally would because of how they are feeling.

Patients struggle to raise residual symptoms with their healthcare provider: of those who had not brought up concerns with their provider, 40% said they do not have the time or energy to start the conversation, and one third do not believe their provider will have a solution to help address their ongoing symptoms.

“These findings reinforce what patients have been telling us for years: far too many continue to struggle despite being on treatment,” said Peter Fang, worldwide vice president of neuroscience and global commercial strategy at Johnson & Johnson. “No one should have to settle for ‘fine’ when it comes to their care, which is why Johnson & Johnson is committed to redefining what is possible for people living with MDD. With Generation Fine, we aim to empower patients and equip them with the tools, resources and confidence to talk to their healthcare providers about moving beyond ‘fine’ and toward remission from their depression.”

At the heart of the campaign are authentic patient stories reflecting the varied challenges and experiences of people living with and managing depression, illustrating just how differently the condition can present. By sharing these stories, Generation Fine seeks to help patients feel less alone, encourage them to expect more from treatment and give them the confidence to take that first step in speaking with their healthcare provider.

“I’ve battled depression at different stages of my life, including during my career in the NFL, and for a long time I felt like I had to ‘tough it out’ and handle it by myself,” said Kyle Long, NFL alum and former Chicago Bears offensive lineman. “When I stopped trying to fight it alone and started being honest with myself and my support system, including my doctor, everything changed. Speaking up about what you’re feeling isn’t weakness, it’s the strongest play you can make.”

“As someone who has navigated my own depression journey, I know firsthand how frustrating it can be when a treatment doesn’t work or address all your symptoms,” said Jessi Gold, psychiatrist and Generation Fine ambassador. “In that moment, it’s easy to settle because the idea of adjusting your treatment plan can feel overwhelming. I want patients to know they’re not alone in this struggle and that they deserve to feel better than ‘fine’, because ‘fine’ is not the finish line.”

---

---

Related Topics and Keywords

depression treatment, Johnson & Johnson